Barrett s Esophagus: Are We Making any Progress?
|
|
- Bennett James
- 6 years ago
- Views:
Transcription
1 3/22/217 arrett s Esophagus: re We Making any Progress? Stuart Jon Spechler, M.D. hief, Division of Gastroenterology, V North Texas Healthcare System; o-director, Esophageal Diseases enter, Professor of Medicine, erta M. and ecil O. Patterson hair in Gastroenterology, UT Southwestern Medical enter Disclosures onsultant: Ironwood Pharmaceuticals 58 year-old man with 2 years of heartburn that has recently increased in frequency and intensity. Traditional oncept Reflux Esophagitis Is a austic, hemical Injury Esophageal Squamous cid urn H auses ell Death, Epithelium Reflux Granulocyte + Infiltration Pepsin H + H + asal ells Lamina Propria Severe, erosive reflux esophagitis How did GERD damage this esophagus? asal ell Death of Surface ells Induces Proliferative Response Rat Model for GERD: Esophago-Duodenostomy Esophagus Duodenum Transected Esophagus Sham-Operated ontrol Stomach Stomach Keratin Esophago- Duodenostomy Why should a caustic injury take weeks to develop? Resulted in severe, ulcerative reflux esophagitis in weeks Souza, Huo,..Spechler. Gastroenterology 29;137:
2 3/22/217 Postoperative Day 3 Submucosal Lymphocyte Infiltration Inflammation did not start in the mucosa Lymphocyte Lymphocyte Mucosa intact Lymphocyte First inflammatory cells were lymphocytes, not granulocytes Souza, Huo,..Spechler. Gastroenterology 29;137:1776. Postoperative Week 3 asal ell and Papillary Surface ells Intact asal ell Papillary asal cell and papillary hyperplasia not due to death of surface cells Souza, Huo,..Spechler. Gastroenterology 29;137:1776. ultures of Esophageal Squamous ells Exposed to cid and ile Salts Secrete IL-8 (a Pro-Inflammatory ytokine) IL-8 Secretion (pg/ml) ells exposed to bile salts (4 M) at ph 4 for 1 minutes TID aseline * Day 1 Day 2 Day 3 Day 4 Day 5 * Souza, Huo,..Spechler. Gastroenterology 29;137:1776. * * Reflux Esophagitis: ytokine-mediated Injury Inflammatory cells mediate epithelial injury, not acid directly Reflux Reflux induces epithelial cells to secrete pro-inflammatory cytokines, H + which attract lymphocytes first, H + ile induce basal cell proliferation ytokine ytokine ytokine ytokine ytokine ytokine Does Reflux Esophagitis in Humans Develop as a ytokine-mediated Injury Rather than a austic hemical Injury? Patients typically have months to years of GERD symptoms before seeking medical attention. - Early histologic changes of reflux esophagitis not evaluated prospectively Severe reflux esophagitis healed by PPIs returns within 6-12 months of stopping PPIs. - Might induce acute reflux esophagitis by temporarily interrupting PPIs in patients with severe GERD? Study of cute Reflux Esophagitis in Humans 12 patients with severe (Los ngeles grade ) reflux esophagitis healed with PPI therapy 11 men, 1 woman Mean age 58 years (SD 13.1 years) Stopped PPIs for 2 weeks to induce acute reflux esophagitis Endoscopy at 1 and 2 weeks after stopping PPIs Dunbar, goston, Souza, Spechler. JM 216;315:214. 2
3 3/22/217 % Total Time ph <4 Esophageal cid Exposure Increases Dramatically When PPIs are Stopped n=1 Median 17.8%* Median 1.2% aseline on PPI 2 weeks off PPI Dunbar, goston, Souza, Spechler. JM 216;315:214. Development of Endoscopic Reflux Esophagitis fter Interruption of PPI Therapy Patient # aseline (on PPIs) Week 1 (off PPIs) Week 2 (off PPIs) Esophagitis Grade Esophagitis Grade Esophagitis Grade Endoscopic Reflux Esophagitis Development Dunbar, goston, Souza, Spechler. JM 216; 315:214. aseline On PPIs arrett s aseline On PPIs 1 Week Off PPIs Dunbar, goston, Souza, Spechler. JM 216;315: Week Off PPIs D3 Immunostaining (T Lymphocytes) Papillary Epithelium asal ell Lamina Propria 3
4 3/22/217 onclusions of cute GERD Study Reflux esophagitis healed by PPIs returns within 2 weeks of stopping PPIs. cute reflux esophagitis is characterized by T-lymphocyte infiltration of esophageal mucosa. Neutrophils and eosinophils not prominent components Findings refute traditional concept that reflux esophagitis is a caustic chemical injury Findings support new concept that refluxed material does not kill esophageal squamous cells directly, but stimulates them to secrete cytokines that attract inflammatory cells that cause tissue damage Dunbar, goston, Souza, Spechler. JM 216;315:214. Stratified Squamous Epithelium Metaplastic olumnar Epithelium arrett s Esophagus The condition in which a metaplastic columnar epithelium that predisposes to cancer development replaces the stratified squamous epithelium that normally lines the distal esophagus ffects 5.6% of adult mericans G Medical Position Statement. Gastroenterology 211;14:184. U.S. Incidence of Esophageal denocarcinoma Has een Rising arrett s Metaplasia Esophageal denocarcinoma Incidence per 1,, Incidence Time Trend 25.6 per million 26 7-Fold Increase In 3 Decades per million Pohl H. ancer Epidemiol iomarkers Prev 21;19:1468. Estimates of ancer Risk for Individual Patients with Non-Dysplastic arrett s Have een Falling 199s Estimate: 1% per year 1 in 1 patients per year Drewitz. m J Gastroenterol 1997;92:212. 2s Estimate:.5% per year 1 in 2 patients per year Shaheen. Gastroenterology 2;119: Estimate:.1%-.3% per year ~1 in 4 patients per year G linical Guideline on Endoscopic Screening for arrett s Esophagus Not recommended for general population or for women Screening may be considered in men with chronic (>5 years) and/or frequent ( weekly) GERD symptoms (heartburn, acid regurgitation) and 2 risk factors ge 5 years White race entral obesity History of smoking Norman onfirmed history of arrett s esophagus or arrett esophageal adenocarcinoma in 1 o relative In women, screening may be considered in individual cases as determined by the presence of multiple risk factors m J Gastroenterol 216;111:3. 4
5 3/22/217 Recommendations for Endoscopic Surveillance of Non-Dysplastic arrett s Esophagus G, SGE, G Surveillance every 3 to 5 years Why Should Proton Pump Inhibitors (PPIs) Prevent ancer in arrett s Esophagus? cid reflux causes reflux esophagitis (chronic inflammation) PPIs heal reflux esophagitis cid causes DN double-strand breaks in arrett s epithelial cells (potentially carcinogenic) PPIs decrease esophageal exposure to this carcinogen cid promotes proliferation in arrett s metaplasia PPIs might prevent proliferation cid stimulates esophageal secretion of proinflammatory and pro-proliferative cytokines cid suppression may prevent cytokine secretion PPIs re Potentially ancer-protective. Why Might PPIs Promote ancer in arrett s Esophagus? PPIs re Potentially ancer-promoting. Pancreatic Enzymes H + Gastrin Gastrin acteria PPI Gastrin increases proliferation in arrett s metaplasia acteria deconjugate bile acids, convert nitrates to N-nitroso compounds Pancreatic enzymes not denatured by gastric acid can reflux into the esophagus Meta-nalysis Studies on Risk of Developing High-Grade Dysplasia (HGD) or denocarcinoma (E) in arrett s Patients on PPIs PPI use associated with Odds 71% Ratio reduction and 95% I in risk of advanced neoplasia Kastelein 213 Jung 211 Hillman 24 Nguyen 29 ltawil 211 Nguyen 21 de Jonge 26 Odds Lower Upper Ratio Limit Limit Favors PPI Favors No PPI Singh S. Gut 214;63:1229. Recent, Large ase-ontrol Studies on Risk of Developing HGD or E in arrett s Patients on PPIs ll pts PPIs in Denmark increase with arrett s the risk of neoplasia? (n=9,883) Relative risk onfounding of developing high-grade by Indication? dysplasia or adenocarcinoma in long-term (>7 years) PPI users: PPI use is not associated with a significant 2.2 (95% I ) low-adherence PPI users decrease in the incidence of esophageal 3.4 (95% I ) high-adherence PPI users adenocarcinoma. Hvid-Jensen F. liment Pharmacol Ther 214;39:984. Population-based general practice registries (UK and NL), pts with arrett s (n=15,134) Odds ratio for developing high-grade dysplasia or adenocarcinoma in long-term (>2 years) PPI users: 1.5 (95% I ) Masclee GM. MJ Open 215;5:e664. rguments Favoring ntireflux Surgery Over PPIs for ancer Prevention in arrett s Esophagus PPIs target acid exclusively, but acid is not the only harmful agent in refluxed gastric juice. Refluxed bile salts might contribute to carcinogenesis. ntireflux surgery can prevent reflux of all gastric material Some small, observational studies suggest that surgically-treated arrett s patients develop less dysplasia and cancer. 5
6 3/22/217 ntireflux Surgery Might Protect gainst ancer in arrett s Esophagus etter than Medical Therapy. Potential advantage is small Not clear that this small, potential advantage justifies the risks of antireflux surgery Norman arrett ge 13 G linical Guideline on Treatment of GERD in arrett s Esophagus Patients with arrett s esophagus should receive once-daily PPI therapy. Routine use of twice-daily dosing is not recommended unless necessitated because of poor control of symptoms or esophagitis. ntireflux surgery should not be pursued in patients with arrett s esophagus as an antineoplastic measure. However, this surgery should be considered in those with incomplete control of reflux symptoms on optimized medical therapy. m J Gastroenterol 216;111:3. Muscularis mucosae HGD T1 T2 Epithelium Lamina propria asement membrane HGD T1 T2 High Grade Dysplasia Intramucosal arcinoma Muscularis mucosae T1a T1b T1b: LN mets >1% Potentially curable with endoscopic therapy Potentially metastatic (1%-2% of cases) Drawing courtesy of Tom Rice Endoscopic therapy is appropriate for neoplasms confined to the mucosa. Drawing courtesy of Tom Rice ccurate T Staging rucial to Determine if urative Endoscopic Therapy Feasible High Grade Dysplasia, Intramucosal arcinoma Lymph node metastases in 1%-2% urative endoscopic therapy feasible Submucosal invasion Lymph node metastases in >1% Failure rate for endoscopic therapy unacceptable Endoscopic mucosal resection (EMR) the best procedure for T staging EMR is as much a staging procedure as it is a therapeutic procedure. If EMR shows submucosal invasion, then endoscopic therapy is not advised. 6
7 3/22/217 Radiofrequency blation (RF) Radiofrequency Energy Generator Radiofrequency blation of arrett s Esophagus losely spaced electrodes blated arrett s Metaplasia Randomized, Sham-ontrolled Trial of Radiofrequency blation for Dysplasia in arrett s Shaheen N et al. N Engl J Med 29;36: Radiofrequency blation of Dysplasia Prevents Neoplastic Progression at One Year % with Progression 3.6% 16.3% Progression of Neoplasia Radiofrequency ablation Sham ablation 9.3% 1.2% Progression to ancer Shaheen. N Engl J Med 29;36: Randomized Trial of RF vs. Surveillance for Low- Grade Dysplasia (LGD) in arrett s Esophagus 136 patients with LGD confirmed by expert pathologist Randomized to RF (68 pts.) or surveillance (68 pts.) Progression to high-grade dysplasia or cancer at 3 years Data 1.5% & RF Safety group Monitoring oard early termination: RF 26.5% superior surveillance to surveillance group for preventing neoplastic progression 25% Potential risk of for progression patient safety issues (95% I if trial %, continued P<.1) Progression to cancer at 3 years 1.5% RF group 8.8% surveillance group 7.4% risk of cancer (95% I -14.7%, P=.3) Phoa KN. JM 214;311:129. Endoscopic Eradication Therapy for Mucosal Neoplasia (Low-Grade or High-Grade Dysplasia, Intramucosal arcinoma) in arrett s Esophagus EMR of mucosal irregularities for staging and therapy - Endoscopists who plan to practice endoscopic ablative procedures should additionally offer EMR. : G Guideline. m J Gastroenterol 216;111:3. Radiofrequency ablation of remaining arrett s metaplasia to minimize metachronous neoplasia 7
8 3/22/217 Surveillance Endoscopy after Endoscopic Eradication Therapy for High-Grade Dysplasia Recurrence rates are substantial 197 patients with HGD/IM had complete eradication of dysplasia and IM Recurrent HGD/IM Recurrence of Neoplasia after omplete Eradication of IM 25% No controlled trials to guide surveillance intervals Follow-Up Months HGD IM Recurrence of Metaplasia after omplete Eradication of IM % HGD IM Follow-Up Months Small J et al. Gastrointest Endosc 215;81:1158. Recurrent IM fter RF, intestinal metaplasia recurs in ~1% per year. Guthikonda et al. m J Gastroenterol 217;112:87. Recurrent Intestinal Metaplasia after RF patients had RF (96% for dysplasia) Number of Recurrences 29 of 32 recurrences 2 endoscopies after at complete GEJ or 1 cm eradication above of intestinal metaplasia (EIM) 15 4-quadrant biopsies at 1 cm intervals throughout ablated area and in gastric cardia denocarcinoma 1 Mean follow-up 3 years Intramucosal 32 patients (16%) had High-Grade recurrence 5 Low-Grade Non-Dysplastic ll visible endoscopically Distance of Recurrence Proximal to GEJ (cm) Suggested biopsy protocol: 8 evenly-spaced biopsies around Z-line, 4-quadrant biopsies 1 and 2 cm above Z-line, biopsies above 2 cm only if visible abnormality otton. Gastrointest Endosc 215;81:1362. G linical Guideline on Management of arrett s Esophagus after Endoscopic Therapy Norman arrett ge 13 Following endoscopic therapy with complete elimination of intestinal metaplasia (EIM), endoscopic surveillance should be continued to detect recurrent metaplasia/dysplasia. Endoscopic surveillance following EIM For patients with HGD or IM: Q 3 months year 1, Q 6 months year 2, and annually thereafter. For patients with LGD: Q 6 months year 1, and annually thereafter. m J Gastroenterol 216;111:3. RF for Non-Dysplastic arrett s Esophagus? Generally requires several endoscopies for complete eradication omplication rate low, but not trivial Substantial rate of recurrence of metaplasia Efficacy in preventing cancer not established Does not eliminate need for surveillance hronic GERD symptoms and 1 risk factor(s) for adenocarcinoma (ge>5, male, white, hiatal hernia, obesity, intra-abdominal body fat, smoking) Knowledge is knowing a tomato is a fruit. No more screening No arrett s onsider screening endoscopy on screening arrett s esophagus No dysplasia Low-grade dysplasia High-grade dysplasia or intramucosal a Surveillance endoscopy every 3-5 yrs Spechler S, Souza R. N Engl J Med 214;371:836. Have diagnosis confirmed by expert pathologist Low-grade dysplasia Endoscopic eradication or surveillance endoscopy every 6-12 months High-grade dysplasia or intramucosal a Endoscopic eradication Wisdom is knowing not to put it in fruit salad. 8
Barrett s Esophagus: Old Dog, New Tricks
Barrett s Esophagus: Old Dog, New Tricks Stuart Jon Spechler, M.D. Chief, Division of Gastroenterology, VA North Texas Healthcare System; Co-Director, Esophageal Diseases Center, Professor of Medicine,
More informationBarrett s Esophagus. Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI
Barrett s Esophagus Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI A 58 year-old, obese white man has had heartburn for more than 20 years. He read a magazine
More informationHistory. Prevalence at Endoscopy. Prevalence and Reflux Sx. Prevalence at Endoscopy. Barrett s Esophagus: Controversy and Management
Barrett s Esophagus: Controversy and Management History Norman Barrett (1950) Chronic Peptic Ulcer of the Oesophagus and Oesophagitis Allison and Johnstone (1953) The Oesophagus Lined with Gastric Mucous
More informationDefinition of GERD American College of Gastroenterology
Definition of GERD American College of Gastroenterology GERD is defined as chronic symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus DeVault et al. Am J
More informationACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus
ACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus Nicholas J. Shaheen, MD, MPH, FACG 1, Gary W. Falk, MD, MS, FACG 2, Prasad G. Iyer, MD, MSc, FACG 3 and Lauren Gerson, MD, MSc, FACG
More informationPresent Day Management of Barrett s Esophagus
Slide 1 Present Day Management of Barrett s Esophagus Kinnari R. Kher, M.D. Slide 2 Goals Risk factors for development of Barrett s esophagus Risks for progression to Esophageal Adenocarcinoma Current
More informationJoel A. Ricci, MD SUNY Downstate Medical Center Department of Surgery
Joel A. Ricci, MD SUNY Downstate Medical Center Department of Surgery Norman Barrett (1950) described the esophagus as: that part of the foregut, distal to the cricopharyngeal sphincter, which is lined
More informationAblation for Barrett s Esophagus: Burn or Freeze
Ablation for Barrett s Esophagus: Burn or Freeze John R. Saltzman MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School Disclosures No relevant disclosures
More informationNew Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus
New Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus Prateek Sharma, MD Key Clinical Management Points: Endoscopic recognition of a columnar lined distal esophagus is crucial
More informationBarrett s esophagus. Barrett s neoplasia treatment trends
Options for endoscopic treatment of Barrett s esophagus Patrick S. Yachimski, MD MPH Director of Pancreatobiliary Endoscopy Assistant Professor of Medicine Division of Gastroenterology, Hepatology & Nutrition
More informationAGA SECTION. Gastroenterology 2016;150:
Gastroenterology 2016;150:1026 1030 April 2016 AGA Section 1027 Procedural intervention (3) Upper endoscopy indications 3 6 Non-response of symptoms to a 4 8 week empiric trial of twice-daily PPI Troublesome
More informationLearning Objectives:
Crescent City GI Update 2018 Ochsner Clinic, NOLA Optimizing Endoscopic Evaluation of Barrett s Esophagus What Should I Do in My Practice? Gregory G. Ginsberg, M.D. Professor of Medicine University of
More informationBarrett s Esophagus: Ablate Everyone?
Nicholas J. Shaheen, MD, MPH, FACG Barrett s Esophagus: Ablate Everyone? Nicholas J. Shaheen, MD, MPH, FACG Center for Esophageal Diseases and Swallowing University of North Carolina Greetings from UNC,
More informationEverything Esophagus: Barrett s Esophagus. Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina
Everything Esophagus: Barrett s Esophagus Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina The Most Important Thing Stayed the Same Adenocarcinoma A
More informationManagement of Barrett s Esophagus. Case Presentation
Management of Barrett s Esophagus Lauren B. Gerson MD, MSc Associate Clinical Professor, UCSF Director of Clinical Research Gastroenterology Fellowship Program California Pacific Medical Center San Francisco,
More informationManagement of Barrett s: From Imaging to Resection
Management of Barrett s: From Imaging to Resection Michael Wallace, MD, MPH, FACG Professor of Medicine Mayo Clinic Florida Goals of Endoscopic Evaluation in Barrett s Detect Barrett s and dysplasia Reduce/eliminate
More informationHistopathology of Endoscopic Resection Specimens from Barrett's Esophagus
Histopathology of Endoscopic Resection Specimens from Barrett's Esophagus Br J Surg 38 oct. 1950 Definition of Barrett's esophagus A change in the esophageal epithelium of any length that can be recognized
More informationGregory G. Ginsberg, M.D.
Radiofrequency Ablation for Barrett s Esophagus with HGD Gregory G. Ginsberg, M.D. Professor of Medicine University of Pennsylvania School of Medicine Abramson Cancer Center Gastroenterology Division Executive
More informationBarrett s Esophagus: What to Do for No Dysplasia, LGD, and HGD?
Barrett s Esophagus: What to Do for No Dysplasia, LGD, and HGD? Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina 1 Outline What are the risks of progression
More informationGastrooesophageal reflux disease. Jera Jeruc Institute of pathology, Faculty of Medicine, Ljubljana, Slovenia
Gastrooesophageal reflux disease Jera Jeruc Institute of pathology, Faculty of Medicine, Ljubljana, Slovenia Reflux esophagitis (RE) GERD: a spectrum of clinical conditions and histologic alterations resulting
More informationThis medical position statement considers a series of
GASTROENTEROLOGY 2011;140:1084 1091 American Gastroenterological Association Medical Position Statement on the Management of Barrett s Esophagus The Institute Medical Position Panel consisted of the authors
More informationMANAGEMENT OF BARRETT S RELATED NEOPLASIA IN 2018
MANAGEMENT OF BARRETT S RELATED NEOPLASIA IN 2018 Sachin Wani Medical Director Esophageal and Gastric Center Division of Gastroenterology and Hepatology University of Colorado Anschutz Medical Campus DISCLOSURES
More informationEndoscopic Management of Barrett s Esophagus
Endoscopic Management of Barrett s Esophagus Sammy Ho, MD Director of Pancreaticobiliary Services and Endoscopic Ultrasound Montefiore Medical Center Barrett s Esophagus Consequence of chronic GERD Mean
More informationBarrett esophagus. Bible class Inselspital
Barrett esophagus Bible class Inselspital 2015.08.10 Guidelines Definition? BSG: ACG: Definition? BSG: ACG: What are the arguments for and against IM as prerequisite for the Dg? What are the arguments
More informationChanges to the diagnosis and management of Barrett s Oesophagus
Changes to the diagnosis and management of Barrett s Oesophagus A review of the new BSG and NICE guidelines and best practice Anjan Dhar DM, MD, FRCPE, AGAF, MBBS (Hons.), Cert. Med. Ed Senior Lecturer
More informationCitation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic management of Barrett s esophagus with dysplasia
UvA-DARE (Digital Academic Repository) Endoscopic management of Barrett s esophagus with dysplasia Phoa, Nadine Link to publication Citation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic
More informationWhat s New in the Management of Esophageal Disease
What s New in the Management of Esophageal Disease Philip O. Katz, MD Chairman, Division of Gastroenterology Einstein Medical Center Philadelphia Clinical Professor of Medicine Jefferson Medical College
More informationSpeaker disclosure. Objectives. GERD: Who and When to Treat 7/21/2015
GERD: Who and When to Treat Eugenio J Hernandez, MD Gastrohealth, PL Assistant Professor of Clinical Medicine, FIU Herbert Wertheim School of Medicine Speaker disclosure I do not have any relevant commercial
More informationGERD DIAGNOSIS & TREATMENT DISCLOSURES 4/18/2018
GERD DIAGNOSIS & TREATMENT Subhash Chandra MBBS Assistant Professor CHI Health Clinic Gastroenterology Creighton University, School of Medicine April 28, 2018 DISCLOSURES None 1 OBJECTIVES Review update
More informationOesophagus and Stomach update dysplasia and early cancer
Oesophagus and Stomach update dysplasia and early cancer Dr Tim Bracey STR teaching 13/4/16 Please check pathkids.com for previous talks One of the biggest units in the country (100 major resections per
More informationIs Radiofrequency Ablation Effective In Treating Barrett s Esophagus Patients with High-Grade Dysplasia?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Radiofrequency Ablation Effective
More informationCurrent Management: Role of Radiofrequency Ablation
Esophageal Adenocarcinoma And Barrett s Esophagus: Current Management: Role of Radiofrequency Ablation Ketan Kulkarni, MD Regional Gastroenterology Associates of Lancaster INTRODUCTION The prognosis of
More informationThe Pathologist s Role in the Diagnosis and Management of Neoplasia in Barrett s Oesophagus Cian Muldoon, St. James s Hospital, Dublin
The Pathologist s Role in the Diagnosis and Management of Neoplasia in Barrett s Oesophagus Cian Muldoon, St. James s Hospital, Dublin 24.06.15 Norman Barrett Smiles [A brief digression - Chair becoming
More informationQuiz Adenocarcinoma of the distal stomach has been increasing in the last 20 years. a. True b. False
Quiz 1 1. Which of the following are risk factors for esophagus cancer. a. Obesity b. Gastroesophageal reflux c. Smoking and Alcohol d. All of the above 2. Adenocarcinoma of the distal stomach has been
More informationRFA and Cyrotherapy for Esophageal Disease
RFA and Cyrotherapy for Esophageal Disease Daniel L. Miller MD Chief, General Thoracic Surgery WellStar Healthcare System/ Mayo Clinic Care Network Clinical Professor of Surgery Medical College of Georgia/
More informationSixteen-year follow-up of Barrett s esophagus, endoscopically treated with argon plasma coagulation
Original Article Sixteen-year of Barrett s esophagus, endoscopically treated with argon plasma coagulation United European Gastroenterology Journal 2014, Vol. 2(5) 367 373! Author(s) 2014 Reprints and
More informationBarrett s Esophagus: State of the Art Management
In the Name of God Barrett s Esophagus: State of the Art Management Siavosh Nasseri-Moghaddam MD, MPH, AGAF Associate Professor of Medicine Digestive Disease Research Center, Shariati Hospital, TUMS IAGH
More informationCurrent Management of Low-Grade Dysplasia in Barrett Esophagus
Current Management of Low-Grade Dysplasia in Barrett Esophagus Gary W. Falk, MD, MS Dr Falk is a professor of medicine in the Division of Gastroenterology at the University of Pennsylvania Perelman School
More informationBurning Issues in the Esophagus
Burning Issues in the Esophagus Elizabeth Montgomery, MD Johns Hopkins Medical Institutions Dr. Montgomery reports no relevant financial relationships with commercial interests. Squamous Epithelium Muscularis
More informationBarrett s Esophagus: Review of Diagnostic Issues and Pre- Neoplastic Lesions
Barrett s Esophagus: Review of Diagnostic Issues and Pre- Neoplastic Lesions Robert Odze, MD, FRCPC Chief, Gastrointestinal Pathology Associate Professor of Pathology Brigham and Women s Hospital Harvard
More informationQuality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care
Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage
More informationESOPHAGEAL CANCER AND GERD. Prof Salman Guraya FRCS, Masters MedEd
ESOPHAGEAL CANCER AND GERD Prof Salman Guraya FRCS, Masters MedEd Learning objectives Esophagus anatomy and physiology Esophageal cancer Causes, presentations of esophageal cancer Diagnosis and management
More informationAmerican Journal of Gastroenterology. Volumetric Laser Endomicroscopy Detects Subsquamous Barrett s Adenocarcinoma
Volumetric Laser Endomicroscopy Detects Subsquamous Barrett s Adenocarcinoma Journal: Manuscript ID: AJG-13-1412.R1 Manuscript Type: Letter to the Editor Keywords: Barrett-s esophagus, Esophagus, Endoscopy
More informationHiatal Hernias and Barrett s esophagus. Dr Sajida Ahad Mercy General Surgery
Hiatal Hernias and Barrett s esophagus Dr Sajida Ahad Mercy General Surgery Objectives Identify the use of different diagnostic modalities for hiatal hernias List the different types of hiatal hernias
More informationDisclosures. Gastroesophageal Reflux Disease. Gastroesophageal Reflux Disease
Kunal Jajoo, MD Brigham and Women s Hospital July 2012 Disclosures Spouse is a physician employed by Boston Scientific Corporation The content of this lecture equitably discusses products of multiple companies
More informationEndoscopic Radiofrequency Ablation or Cryoablation for Barrett s Esophagus
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett s Esophagus Policy Number: 2.01.80 Last Review: 6/2018 Origination: 6/2012 Next Review: 6/2019 Policy Blue Cross and Blue Shield of Kansas
More informationHow to remove BE cancer: EMR or ESD? Expected outcome
How to remove BE cancer: EMR or ESD? Expected outcome Presented by Horst Neuhaus Institution Dpt. of Gastroenterology Evangelisches Krankenhaus Düsseldorf, Germany Indications for endoscopic resection
More informationMedicare Advantage Medical Policy
Medicare Advantage Medical Policy Current Policy Effective Date: 1/1/18 Title: Endoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus Description/Background Barrett Esophagus and the
More informationACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus
30 PRACTICE GUIDELINES nature publishing group CME ACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus Nicholas J. Shaheen, MD, MPH, FACG 1, Gary W. Falk, MD, MS, FACG 2, Prasad G.
More informationQuality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care
Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process DESCRIPTION: Percentage
More informationChapter 12: Training in Pathology. DDSEP Chapter 13: Question 19
DDSEP Chapter 13: Question 19 A 70 year-old male with a history of celiac disease diagnosed in his forties reports abdominal pain, dark stools, and 20-pound weight loss. He reports complete compliance
More informationCryospray ablation using pressurized CO 2 for ablation of Barrett s esophagus with early neoplasia: early termination of a prospective series
E17 Cryospray ablation using pressurized CO 2 for ablation of Barrett s esophagus with early neoplasia: early termination of a prospective series Authors Romy E. Verbeek 1, Frank P. Vleggaar 1, Fiebo J.
More informationIs intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia?
Diseases of the Esophagus (2007) 20, 36 41 DOI: 10.1111/j.1442-2050.2007.00638.x Blackwell Publishing Asia Original article Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of
More informationBarrett s Esophagus. Radiofrequency Ablation with the HALO Technology A Reference Book
Radiofrequency Ablation with the HALO Technology A Reference Book 540 Oakmead Parkway, Sunnyvale, CA 94085 What is Barrett s esophagus? Barrett s esophagus is a change that occurs within the cellular lining
More informationSAM PROVIDER TOOLKIT
THE AMERICAN BOARD OF PATHOLOGY Maintenance of Certification (MOC) Program SAM PROVIDER TOOLKIT Developing Self-Assessment Modules (SAMs) www.abpath.org The American Board of Pathology (ABP) approves educational
More informationBarrett's Esophagus: Sorting Out the Controversy
Barrett's Esophagus: Sorting Out the Controversy Learning Objectives 1. Identify the challenges in screening for Barrett s esophagus 2. Demonstrate comprehension of the risk of progression of Barrett s
More informationVolumetric laser endomicroscopy can target neoplasia not detected by conventional endoscopic measures in long segment Barrett s esophagus
E318 Volumetric laser endomicroscopy can target neoplasia not detected by conventional endoscopic measures in long segment esophagus Authors Institution Arvind J. Trindade, Benley J. George, Joshua Berkowitz,
More informationEndoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus Policy Number: Original Effective Date: MM.02.005 09/01/2010 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
More informationFaculty Disclosure. Objectives. State of the Art #3: Referrals for Gastroscopy (focus on common esophagus problems) 24/11/2014
State of the Art #3: Referrals for Gastroscopy (focus on common esophagus problems) Dr. Amy Morse November 2014 Faculty: Amy Morse Faculty Disclosure Relationships with commercial interests: Grants/Research
More informationSection: Medicine Effective Date: July 15, 2015 Subsection: Original Policy Date: December 7, 2011 Subject:
Last Review Status/Date: June 2015 Page: 1 of 16 Cryoablation for Barrett s Esophagus Description Barrett s esophagus (BE) is a condition in which the normal squamous epithelium is replaced by specialized
More informationPrognostic analysis of gastric mucosal dysplasia after endoscopic resection: A single-center retrospective study
JBUON 2019; 24(2): 679-685 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Prognostic analysis of gastric mucosal dysplasia after endoscopic resection:
More informationIn 1998, the American College of Gastroenterology issued ALIMENTARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1232 1236 ALIMENTARY TRACT Effects of Dropping the Requirement for Goblet Cells From the Diagnosis of Barrett s Esophagus MARIA WESTERHOFF,* LINDSEY HOVAN,
More informationGastrointestinal pathology 2018 lecture 2. Dr Heyam Awad FRCPath
Gastrointestinal pathology 2018 lecture 2 Dr Heyam Awad FRCPath Eosinophilic esophagitis Incidence of eosinophilic gastritis is increasing. Symptoms: food impaction and dysphagia. Histology: infiltration
More informationThe normal esophagus is lined with squamous epithelium.
.. ALAN J. CAMERON, M.D. In Barrett's esophagus, the squamous lining of the lower esophagus is replaced by columnar epithelium. Barrett's esophagus is associated with gastroesophageal reflux and an increased
More informationBarrett s Oesophagus Information Leaflet THE DIGESTIVE SYSTEM. gutscharity.org.
THE DIGESTIVE SYSTEM http://healthfavo.com/digestive-system-for-kids.html This factsheet is about Barrett s Oesophagus Barrett s Oesophagus is the term used for a pre-cancerous condition where the normal
More informationChapter 2 Complications of Gastroesophageal Reflux Disease
Chapter 2 Complications of Gastroesophageal Reflux Disease Patrick Yachimski Acute esophageal exposure to gastric and/or duodenal refluxate can result in pyrosis and symptomatic gastroesophageal reflux
More informationEndoscopic Radiofrequency Ablation or Cryoablation for Barrett`s Esophagus. Original Policy Date
MP 2.01.52 Endoscopic Radiofrequency Ablation or Cryoablation for Barrett`s Esophagus Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationBarrett s Esophagus: State of the Art. Food Getting Stuck
Barrett s Esophagus: State of the Art Nicholas J. Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina SOM Food Getting Stuck 73-year-old retired Wilmington police
More informationEditorial: Advanced endoscopic therapeutics in Barrett s neoplasia; where are we now and where are we heading?
Editorial: Advanced endoscopic therapeutics in Barrett s neoplasia; where are we now and where are we heading? Dr. Gaius Longcroft-Wheaton MB,BS, MD, MRCP(UK), MRCP(Gastro) Consultant gastroenterologist
More informationFrom reflux to esophageal cancer. Josh Boys, MD TCV 2 nd year indentured servant
From reflux to esophageal cancer Josh Boys, MD TCV 2 nd year indentured servant The Pathway Esophageal Squamous epithelium+reflux Columnar lined esophagus (CLE) or Cardiac mucosa Intestinal Metaplasia
More informationTreat Barrett s, Remove the Risk. HALO System
Treat Barrett s, Remove the Risk HALO System The HALO 360 System Advanced Ablation Technology for Barrett s Esophagus The HALO 360 System is designed to remove the Barrett s epithelium in a short, well-tolerated
More informationCommon Inflammatory Gastrointestinal Disorders: Endoscopic and Pathologic Correlations
Common Inflammatory Gastrointestinal Disorders: Endoscopic and Pathologic Correlations Nicole C. Panarelli, M.D. Attending Pathologist Montefiore Medical Center Associate Professor of Pathology - Albert
More informationGland ducts and multilayered epithelium in mucosal biopsies from gastroesophageal-junction region are useful in characterizing esophageal location
Diseases of the Esophagus (2005) 18, 87 92 2005 ISDE Blackwell Publishing, Ltd. Original article Gland ducts and multilayered epithelium in mucosal biopsies from gastroesophageal-junction region are useful
More informationmalignant polyp Daily Challenges in Digestive Endoscopy for Endoscopists and Endoscopy Nurses BSGIE Annual Meeting 18/09/2014 Mechelen
Plan Incidental finding of a malignant polyp 1. What is a polyp malignant? 2. Role of the pathologist and the endoscopist 3. Quantitative and qualitative risk assessment 4. How to decide what to do? Hubert
More informationGastric Polyps. Bible class
Gastric Polyps Bible class 29.08.2018 Starting my training in gastroenterology, some decades ago, my first chief always told me that colonoscopy may seem technically more challenging but gastroscopy has
More informationHenry Moon was one of the giants in academic pathology during my early years.
Henry Moon was one of the giants in academic pathology during my early years. Controversial stuff that occurs slightly above, within or slightly below the gastroesophageal junction, including Barrett s
More informationAccepted Manuscript. CGH Editorial: Sound the Alarm for Barrett s Screening! Tarek Sawas, M.D., M.P.H., David A. Katzka, M.D
Accepted Manuscript CGH Editorial: Sound the Alarm for Barrett s Screening! Tarek Sawas, M.D., M.P.H., David A. Katzka, M.D PII: S1542-3565(18)31093-0 DOI: 10.1016/j.cgh.2018.10.010 Reference: YJCGH 56132
More informationSAMs Guidelines DEVELOPING SELF-ASSESSMENT MODULES TEST QUESTIONS. Ver. #
SAMs Guidelines DEVELOPING SELF-ASSESSMENT MODULES TEST Ver. #5-02.12.17 GUIDELINES FOR DEVELOPING SELF-ASSESSMENT MODULES TEST The USCAP is accredited by the American Board of Pathology (ABP) to offer
More informationESOPHAGEAL CANCER. Epidemiology 3/22/2017. Esophageal Carcinoma: subtypes. Esophageal Adenocarcinoma (EAC) Epidemiology.
ESOPHAGEAL CANCER Disclosures Sushil Ahlawat, MD, FACP, FASGE, AGAF Associate Professor of Medicine Director of Endoscopy RUTGERS NJMS Nothing to disclose. Esophageal Carcinoma: subtypes Subtype Squamous
More informationPatterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett s esophagus
Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett s esophagus Robert J. Korst, MD, a,b Sobeida Santana-Joseph, MSN, a,b John R. Rutledge, MAS,
More informationEvaluating Treatments of Barrett s Esophagus That Shows High-Grade Dysplasia
...PRESENTATIONS... Evaluating Treatments of Barrett s Esophagus That Shows High-Grade Dysplasia Based on a presentation by Bergein F. Overholt, MD Presentation Summary Thermal ablation and surgery are
More informationBarrett Esophagus - RadioFrequency Ablation (BE-RFA) - Project manual + FAQ
Barrett Esophagus - RadioFrequency Ablation (BE-RFA) - Project manual + FAQ Table of contents 1 General project information...3 1.1 Inclusion criteria...3 1.2 Registration time points...3 1.3 Project variable
More informationEosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis (EoE) 01.06.2016 EoE: immune-mediated disorder food or environmental antigens => Th2 inflammatory response. Key cytokines: IL-4, IL-5, and IL-13 stimulate the production of eotaxin-3
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Transfer of Health Information and Interoperability 2019 COLLECTION TYPE:
More informationGastrointestinal Tract Cancer
Gastrointestinal Tract Cancer Tumors of the Stomach Gastric adenocarcinoma Incidence and Epidemiology Incidence mortality rates USA High incidence: Japan, China, Chile, Ireland risk lower socioeconomic
More informationGreater Manchester & Cheshire Guidelines for Pathology Reporting of Oesophageal and Gastric Malignancy
Greater Manchester & Cheshire Guidelines for Pathology Reporting of Oesophageal and Gastric Malignancy Authors: Dr Stephen Hayes, Dr David Bisset, Dr Gordon Armstrong, Dr Sue Pritchard 1. General Comments
More informationDisclosures. Heartburn and Barrett s Esophagus. Heartburn and Barrett s Esophagus. GERD is common in the U.S. None
Heartburn and Barrett s Esophagus None Disclosures Christian Mathy, MD University of California, San Francisco 2015 Heartburn and Barrett s Esophagus Heartburn and GERD GERD therapy Extraesophageal GERD
More informationENDOLUMINAL THERAPIES FOR GERD. University of Colorado Department of Surgery Grand Rounds March 31st, 2008
ENDOLUMINAL THERAPIES FOR GERD University of Colorado Department of Surgery Grand Rounds March 31st, 2008 Overview GERD Healthcare significance Definitions Treatment objectives Endoscopic options Plication
More informationEsophageal Adenocarcinoma: Pathogenesis, Prevention, and Prognosis
Department of General Thoracic and Esophageal Surgery, Heart and Lung Center Helsinki University Hospital, Helsinki, Finland And Department of Gastrointestinal Surgery, Abdominal Center Helsinki University
More informationPrinciples of diagnosis, work-up and therapy The Gastroenterologist s role
Principles of diagnosis, work-up and therapy The Gastroenterologist s role Dr. Christos G. Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University
More informationEndoscopic Submucosal Dissection ESD
Endoscopic Submucosal Dissection ESD Peter Draganov MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Florida Gastrointestinal Cancer Lesion that Can be Treated
More informationWhat Is Barrett s Esophagus?
What Is Barrett s Esophagus? Having Barrett s esophagus means the cells lining the esophagus (the tube that links the mouth and the stomach) have changed into types of intestinal cells that are not normal
More informationEarlyoesophagealcancer. dr. Nina Zidar Institute of Pathology Faculty ofmedicine University of Ljubljana Slovenia
Earlyoesophagealcancer dr. Nina Zidar Institute of Pathology Faculty ofmedicine University of Ljubljana Slovenia Early carcinoma of oesophagus = tumor limited to mucosa or submucosa, not extending into
More informationIt has been estimated that 5.6% of adults in the United States have
The new england journal of medicine review article Dan L. Longo, M.D., Editor Barrett s Esophagus Stuart J. Spechler, M.D., and Rhonda F. Souza, M.D. From the Esophageal Diseases Center, Department of
More informationEndoscopic therapy of Barrett s esophagus Oliver Pech and Christian Ell
Endoscopic therapy of Barrett s esophagus Oliver Pech and Christian Ell Department of Internal Medicine 2, HSK Wiesbaden, Wiesbaden, Germany Correspondence to Oliver Pech, MD, PhD, Department of Gastroenterology,
More informationThe increasing incidence of esophageal adenocarcinoma
GASTROENTEROLOGY 2004;127:310 330 A Critical Review of the Diagnosis and Management of Barrett s Esophagus: The AGA Chicago Workshop PRATEEK SHARMA,* KENNETH MCQUAID, JOHN DENT, M. BRIAN FENNERTY, RICHARD
More informationEosinophilic Esophagitis: The New Kid on the Block
6/9/215 Eosinophilic Esophagitis: The New Kid on the Block Consultant: Takeda Disclosures Stuart Jon Spechler, M.D. Chief, Division of Gastroenterology, VA North Texas Healthcare System; Co-Director, Esophageal
More informationCitation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic management of Barrett s esophagus with dysplasia
UvA-DARE (Digital Academic Repository) Endoscopic management of Barrett s esophagus with dysplasia Phoa, Nadine Link to publication Citation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic
More informationEndoscopic management of Barrett s esophagus:european Society of Gastrointestinal Endoscopy (ESGE) Position Statement
Endoscopic management of Barrett s esophagus:european Society of Gastrointestinal Endoscopy (ESGE) Position Statement Authors Bas Weusten 1, 2,RafBisschops 3,EmanuelCoron 4,MárioDinis- Ribeiro 5,Jean-MarcDumonceau
More informationRings in the esophagus are not always eosinophilic esophagitis: Case series of ring forming lymphocytic esophagitis and review of the literature
Rings in the esophagus are not always eosinophilic esophagitis: Case series of ring forming lymphocytic esophagitis and review of the literature Authors Julia L. Pleet 1,SofiaTaboada 2, Arvind Rishi 2,
More information